Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device

Not Applicable

Recruiting

• Conditions: Breast Cancer, Metastatic; Breast Cancer Invasive; Breast Cancer Early Stage Breast Cancer (Stage 1-3)

• Registration Number: NCT06807502
• Lead Sponsor: ScreenCell

Brief Summary

Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.

The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-01-14
• Study First Submitted QC: 2025-01-28
• Study First Posted: 2025-02-04
• Study Start: 2025-02-24
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-10
• Last Update Posted: 2025-03-11
• Primary Completion: 2026-09-30
• Study Completion: 2026-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 93

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Evolution of the kinetics of CTC during treatment	From enrollement to the end of follow up at 9 months	Evolution of the number of CTC isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients. Average number of CTCs measured during the study (D0, W6, W12, W24, W36)

Secondary Outcome Measures

Name	Time	Method
Molecular characterisation of CTC	From enrollement to the end of follow up at 9 months	Analysis of the expression of specific antigens and the presence of informative mutations on CTCs isolated by ScreenCell technology thanks to a blood draw during the therapeutic management of metastatic and infiltrative non-metastatic breast cancer patients during the study (D0, W6, W12, W24, W36)

Trial Locations

Locations (1)

CMC Ambroise Paré Hartmann; 🇫🇷 Neuilly-Sur-Seine, France